Deborah Heart and Lung Center
Browns Mills, New Jersey, 08015, United States
NCT Number: NCT02803775
Cardiac resynchronization therapy (CRT) is a well established clinical therapy for patients with symptomatic left ventricular systolic dysfunction and electrocardiographic QRS duration of 120 ms or greater. Multicenter trials have consistently demonstrated CRT "non responder" rates of 32-43% at 6 months. Subsequent studies have shown that utilizing echocardiographic-guided device reprogramming for optimal atrio-ventricular (A-V) and interventricular (VV) delays at rest have improved clinical response. Recently, an echocardiographically validated automated pacemaker programmer-based intra-cardiac electrogram (IEGM) algorithm has been developed for rapid optimization of sino-ventricular (P-V), A-V and V-V delays at resting heart rates that is partially based on the interventricular conduction time delays. Nevertheless, controversy still persists as to the applicability of both echocardiographic and IEGM derived algorithms at elevated heart rates, as with physical activity, when patients are more likely to experience symptoms related to poor cardiac output.
Recent studies have shown clinical benefits of pacing from sites of late intrinsic activation or intra-ventricular conduction delays (IVCD). Some studies have utilized the intrinsic SENSED IVCD method while others used the right ventricle (RV)-PACED IVCD. There have not been any studies to date that compare both methods to determine if one may yield a better clinical outcome with lower non-responder rates.
This study predicts that the RV paced IVCD method will provide better clinical outcomes than the longest RV sensed IVCD as determined by the clinical composite score.
The study is a prospective double blind study with an additional cross-over group consisting only of non-responders to compare the clinical response in 72 patients receiving CRT therapy. After successful CRT-D implantation and before hospital discharge patients will be randomly assigned in a 1:1 fashion to Group 1 (SENSED) or Group 2 (PACED). The patient will complete a Minnesota Living with Heart Failure questionnaire, compare echocardiographic data and be assessed by a blinded nurse and physician prior to discharge and at each follow up visit to maintain the double blind design.
After 3 months of follow-up, non-responders from each group will be crossed-over to the other group and followed for an additional 3 months. Clinical data will be collected at the end of that 3 months and compared looking at changes in symptoms, ejection fraction (EF) and other echocardiographic measurements, New York Heart Assocation Function Class ( NYHA) class, clinical composite scores (CCC), device interrogation data and hospital admissions between the two groups to see if there is a statistical difference.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Browns Mills, New Jersey, 08015, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Programming based on Electrogram measurement
Time frame: Baseline, 3 months and 6 months. The six month assessment is optional for non-responders participating in crossover option
Six-minute walk distance (measured in meters)
Time frame: Baseline, 3 months and 6 months. The six month assessment is optional for non-responders participating in crossover option
Packer Clinical Composite Score Questionnaire captures the following outcomes: death (yes/no field), hospitalizations (yes/no field), global patient assessment (likert scale 1-5 points) , functional heart class (I, II, III, IV).
Deborah Heart and Lung Center
Other
Acronym: PASED
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05574699
Cardiovascular Diseases, Chronic Disease
Baltimore, Maryland, United States
View Trial DetailsNCT06526884
AKI - Acute Kidney Injury, Acute Kidney Injury
Los Angeles, California, United States
View Trial DetailsNCT01994252
Arrhythmias, Cardiac, Atrial Fibrillation
Calgary, Alberta, Canada
View Trial DetailsNCT05209880
Cardiovascular Diseases, Chronic Disease
Boston, Massachusetts, United States
View Trial Details